Pres­i­dent Don­ald Trump is ex­pect­ed to nom­i­nate Hei­di Over­ton to be the next FDA com­mis­sion­er, ac­cord­ing to a source fa­mil­iar with the de­ci­sion, set­ting a...

List prices for brand-name drugs have de­clined sig­nif­i­cant­ly in 2026. But the rea­sons be­hind it may have more to do with a Biden-era law than...

The FDA's next five-year reau­tho­riza­tion of the pre­scrip­tion drug user fee pro­gram will fea­ture new in­cen­tives for do­mes­tic phar­ma com­pa­nies, new­ly sped up re­views for...

Sev­en large drug­mak­ers and lob­by­ing groups PhRMA and BIO have called up­on the Ger­man gov­ern­ment to re­vise some of its new drug pric­ing poli­cies as...

Af­ter a low­er court re­ject­ed Teva's case last fall, a fed­er­al ap­peals court has re­vived part of the drug­mak­er’s law­suit against Medicare ne­go­ti­a­tions.

The DC...

Eu­ro­pean reg­u­la­tors on Thurs­day ex­plained last week's de­ci­sion to pull Am­gen's rare dis­ease drug Tavneos from the mar­ket there, de­tail­ing their skep­ti­cism about the da­ta...